Archive

Fezolinetant cuts hot flashes for almost 6 months

Written by Bruce Sylvester | 14 May 2024

Fezolinetant 45 mg appears to be effective for up to 24 weeks in the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause in women who are considered… read more.

MHRA approves Veoza (fezolinetant) to treat vasomotor symptoms associated with menopause – Astellas

Written by Charlie King | 23 Dec 2023

Veoza (Veozah in the US), also known as fezolinetant, from Astellas, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) after receiving similar approval in… read more.

European Commission approves Veoza (fezolinetant) to treat vasomotor symptoms associated with menopause – Astellas

Written by Charlie King | 18 Dec 2023

Astellas Pharma Inc. announced the European Commission (EC) on December 7 approved Veoza (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS)… read more.

CHMP positive for Vezoa (fezolinetant) to treat vasomotor symptoms associated with menopause – Astellas Pharma

Written by Charlie King | 23 Oct 2023

Astellas Pharma Inc. announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on October 12 adopted a positive opinion relating to… read more.

Phase IIIb trial of fezolinetant shows positive topline results for treatment of vasomotor symptoms – due to menopause – Astellas

Written by Charlie King | 17 Jul 2023

Astellas Pharma Inc. announced positive topline results from the Phase IIIb DAYLIGHT clinical trial for fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate… read more.